Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

Andrew J. Greenfield net worth and biography

Andrew Greenfield Biography and Net Worth

VP of Abiomed

Mr. Andrew J. Greenfield is a vice president and chief commercial officer at Abiomed. Mr. Greenfield has served as an executive officer of Abiomed since 2005. In addition to overseeing our global commercial operations, Mr. Greenfield oversees government affairs, reimbursement, global marketing, Asia Pacific and physician programs.

Before joining Abiomed, Mr. Greenfield held positions in sales, marketing and finance at GE Healthcare including consulting with large U.S. health systems, eCommerce and Six Sigma from 1999 to 2005. Prior to GE Healthcare, he held positions in sales, marketing and finance at The Boeing Company, including European Country Manager, and is a graduate of the Fiscal Development Program.

He is currently chairman-elect and executive committee member for MassMEDIC in Boston, MA, a public-private partnership that coordinates the resources used in managing medical devices to improve patient access to cutting-edge medical technology. He is a past executive committee member with the Medical Device Innovation Consortium (MDIC) which is advancing safer and more cost-effective innovations that benefit patients through a collaboration between the Centers for Medicare & Medicaid (CMS), Food and Drug Administration (FDA), industry and patients.

Mr. Greenfield received his bachelor’s degree in finance from the University of Illinois and Master of Business Administration degree from St. Louis University. He is also a certified Master Blackbelt in Six Sigma and Change Acceleration Process from GE. Originally from Forreston, Illinois, he now resides in Massachusetts with his family.

What is Andrew J. Greenfield's net worth?: The estimated net worth of Andrew J. Greenfield is at least $14.07 million as of January 28th, 2021. Mr. Greenfield owns 36,930 shares of Abiomed stock worth more than $14,071,069 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Greenfield may own. Additionally, Mr. Greenfield receives a salary of $804,950.00 as VP at Abiomed. Learn More about Andrew J. Greenfield's net worth.
How old is Andrew J. Greenfield?: Mr. Greenfield is currently 50 years old. There are 6 older executives and no younger executives at Abiomed. The oldest executive at Abiomed is Dr. David M. Weber Ph.D., Scientific & Technology Advisor, who is 62 years old. Learn More on Andrew J. Greenfield's age.
What is Andrew J. Greenfield's salary?: As the VP of Abiomed, Inc., Mr. Greenfield earns $804,950.00 per year. There are 4 executives that earn more than Mr. Greenfield. The highest earning executive at Abiomed is Mr. Michael R. Minogue, Chairman, CEO & Pres, who commands a salary of $3,040,000.00 per year. Learn More on Andrew J. Greenfield's salary.
How do I contact Andrew J. Greenfield?: The corporate mailing address for Mr. Greenfield and other Abiomed executives is 22 CHERRY HILL DR, DANVERS MA, 01923. Abiomed can also be reached via phone at (978) 646-1400 and via email at [email protected]. Learn More on Andrew J. Greenfield's contact information.
Has Andrew J. Greenfield been buying or selling shares of Abiomed?: Andrew J. Greenfield has not been actively trading shares of Abiomed during the last quarter. Most recently, Andrew J. Greenfield sold 5,000 shares of the business's stock in a transaction on Thursday, January 28th. The shares were sold at an average price of $366.00, for a transaction totalling $1,830,000.00. Following the completion of the sale, the vice president now directly owns 36,930 shares of the company's stock, valued at $13,516,380. Learn More on Andrew J. Greenfield's trading history.
Who are Abiomed's active insiders?: Abiomed's insider roster includes Marc Began (VP), Andrew Greenfield (VP), Michael Minogue (CEO), Michael Minogue (CEO), Dorothy Puhy (Director), Joseph Riccelli, Sr. (CEO), Martin Sutter (Director), Paul Thomas (Director), Todd Trapp (CFO), David Weber (COO), and Magdalena Yesil (Director). Learn More on Abiomed's active insiders.

Andrew J. Greenfield Insider Trading History at Abiomed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/28/2021	Sell	5,000	$366.00	$1,830,000.00	36,930
12/29/2020	Sell	5,000	$321.00	$1,605,000.00	26,930
12/22/2020	Sell	7,156	$295.87	$2,117,245.72
8/29/2018	Sell	4,440	$395.00	$1,753,800.00
2/20/2018	Sell	20,000	$270.36	$5,407,200.00
10/2/2017	Sell	11,282	$169.32	$1,910,268.24
3/17/2017	Sell	10,000	$124.00	$1,240,000.00	66,307
6/7/2016	Sell	9,000	$104.16	$937,440.00	65,234
4/18/2016	Sell	10,000	$99.10	$991,000.00	61,186
3/31/2016	Sell	15,000	$94.11	$1,411,650.00	58,941
3/22/2016	Sell	24,800	$89.06	$2,208,688.00	73,614
3/21/2016	Sell	19,572	$89.07	$1,743,278.04	73,614
3/10/2016	Sell	200	$89.00	$17,800.00	54,242
6/15/2015	Sell	3,185	$65.00	$207,025.00
5/7/2015	Sell	3,500	$71.00	$248,500.00
10/31/2014	Sell	15,000	$31.90	$478,500.00
5/27/2014	Sell	7,026	$21.10	$148,248.60
5/23/2013	Sell	1,666	$21.63	$36,035.58

Andrew J. Greenfield Buying and Selling Activity at Abiomed

Abiomed Company Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Today's Range

Now: $381.02

$381.02

50 Day Range

MA: $380.55

$377.20

$381.30

2 Week Range

Now: $381.02

$219.85

$381.99

Volume

258 shs

Average Volume

611,028 shs

Market Capitalization

$17.18 billion

P/E Ratio

65.47

Dividend Yield

N/A

Beta

1.4

Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

From GoldenCrest Metals | Ad

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

Learn More Now

Andrew Greenfield Biography and Net Worth

What is Andrew J. Greenfield's net worth?

How old is Andrew J. Greenfield?

What is Andrew J. Greenfield's salary?

How do I contact Andrew J. Greenfield?

Has Andrew J. Greenfield been buying or selling shares of Abiomed?

Who are Abiomed's active insiders?